CJC-1295 NO DAC is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). This variant omits the DAC (Drug Affinity Complex) albumin-binding modification, which differentiates it clearly from CJC-1295 With DAC. Removing the DAC moiety shortens its in-vivo half-life and eliminates prolonged binding to serum albumin, granting researchers greater controllability over peptide exposure duration in experimental setups.

This peptide binds specifically to GHRH receptors expressed on pituitary somatotroph cells, stimulating the pulsatile release of endogenous growth hormone. Instead of supplying exogenous GH directly, it activates the body’s inherent endocrine feedback pathway, making it a valuable research tool to investigate pituitary hormone regulation, body composition shifts and endocrine signal transduction. Researchers commonly apply this compound in cell assays and animal models to explore endocrine rhythm and metabolic response.

Our CJC-1295 NO DAC is produced by solid-phase peptide synthesis and refined by multi-stage preparative HPLC purification. As a longer linear peptide, incomplete coupling reactions during synthesis may produce truncated fragments. Each batch undergoes mass spectrometry verification to validate full sequence integrity, while HPLC chromatograms monitor impurity levels to maintain consistent quality between batches. Lyophilization stabilizes the peptide structure and preserves bioactivity throughout transit and frozen long-term storage.

Once reconstituted into liquid form, the peptide becomes susceptible to protease degradation and thermal damage. It is highly recommended to split the reconstituted solution into small single-use aliquots right after dissolution. Repeated freezing and thawing will degrade peptide chains and reduce biological activity. Operators must follow standard laboratory safety protocols and wear protective equipment while weighing powder and preparing working solutions.